Search
bimekizumab-bkzx
Indications:
- investigational drug for treatment of moderate-to-severe plaque psoriasis [1]
- treatment of hidradenitis suppurativa in adults [2] (FDA-approved Nov 2024)
Mechanism of action:
- humanized lgG1 monoclonal antibody
- inhibits IL-17, IL17A & IL17F
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Bassett M
Psoriasis Falls to Novel Biologic
Bimekizumab brings clear or almost clear skin to vast majority
of patients in phase II trial.
MedPage Today. February 19, 2018
https://www.medpagetoday.com/meetingcoverage/aad/71243
- Papp K, et al
Dual neutralization of interleukin (IL)-17A and IL-17F with
bimekizumab in moderate-to-severe psoriasis: Results from a
phase 2b, randomized, double-blinded, placebo-controlled,
dose-ranging study.
American Academy of Dermatology (AAD) 2018
- Bosworth T
Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target.
Medscape. March 20, 2023
https://www.medscape.com/viewarticle/989861
- Dowd K
FDA approves Bimzelx for adults with moderate to severe hidradenitis suppurativa.
Healio. Nov 20, 2024
https://www.healio.com/news/dermatology/20241120/fda-approves-bimzelx-for-adults-with-moderate-to-severe-hidradenitis-suppurativa
- AMA Morning Rounds. Nov 21, 2024
American Medical Association